Value Sense
POAI
Predictive Oncology Inc. (POAI)
Last Price$1.3(9.4%)
Market Cap$8,155.2K
LTM Rule of 40 (EBIT margin)
(982.0%)
5Y avg
(1,127.4%)
Medical - Instruments & Supplies industry median
(8.0%)
Stock quality & Intrinsic value
4/10
3.0% undervalued
POAI
is 297.3% undervalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

Predictive Oncology Inc. Rule of 40 (EBIT margin)

Annual
Quarterly
LTM
Industry median
Company stand-alone
POAI
Healthcare
Crunching data... Almost there!
Dec'08Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Rule of 40 (EBIT margin)
0.0%
0.0%
(418,714.8%)
29,206.3%
(3,697.4%)
(1,759.1%)
(576.4%)
(703.6%)
(1,459.8%)
(1,139.5%)
(441.3%)
(975.8%)
(64.5%)
(934.8%)
(1,008.2%)
(763.8%)
POAI
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for POAI and see if it's the right time to invest.
Dive in

Predictive Oncology Inc. (POAI) Rule of 40 (EBIT margin) comparison analysis

General

LTM Rule of 40 (EBIT margin)

OTHER METRICS

Company name

Revenue growth

EPS growth

Net Income margin

Predictive Oncology Inc. logo
Predictive Oncology Inc.POAI
(982.0%)
18.2%
(64.9%)
(785.6%)
Median Peer Set
18.3%
3.4%
23.0%
10.4%
Intuitive Surgical, Inc. logo
Intuitive Surgical, Inc.ISRG
45.4%
17.2%
27.7%
27.8%
ResMed Inc. logo
ResMed Inc.RMD
44.5%
10.9%
13.4%
21.8%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
26.5%
8.4%
32.2%
10.1%
Hologic, Inc. logo
Hologic, Inc.HOLX
25.7%
(0.0%)
81.1%
19.6%
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
18.7%
4.2%
18.3%
8.4%
West Pharmaceutical Services, Inc. logo
West Pharmaceutical Services, Inc.WST
17.9%
(1.9%)
(15.5%)
17.0%
Alcon Inc. logo
Alcon Inc.ALC
17.8%
8.5%
182.9%
10.3%
AptarGroup, Inc. logo
AptarGroup, Inc.ATR
16.9%
2.7%
30.2%
10.5%
Masimo Corporation logo
Masimo CorporationMASI
(10.5%)
0.6%
(42.5%)
4.0%
Baxter International Inc. logo
Baxter International Inc.BAX
(15.1%)
(69.5%)
(100.0%)
(6.9%)

POAI key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Dec'08Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Revenue
% growth
0.0
0.0%
0.0
0.0%
0.0
(98.2%)
0.1
33,454.5%
0.2
95.3%
0.5
148.0%
1.0
103.3%
0.7
(31.2%)
0.5
(30.2%)
0.7
43.4%
1.4
115.6%
1.4
(0.0%)
1.3
(11.3%)
1.4
13.4%
1.5
6.0%
1.8
18.2%
Cost of Goods Sold (COGS)0.00.00.00.10.10.20.40.30.20.10.40.50.40.50.50.6
Gross Profit
% margin
0.0
0.0%
0.0
55.5%
0.0
51.4%
0.0
42.0%
0.1
31.9%
0.3
59.5%
0.6
59.5%
0.4
53.5%
0.3
60.2%
0.5
77.4%
1.0
70.5%
0.9
62.3%
0.8
64.3%
0.9
65.7%
1.0
66.4%
1.1
64.3%
Operating Expenses1.72.51.24.17.29.27.04.86.88.38.914.713.314.416.315.1
Research & Development Expenses (R&D)0.00.00.00.00.00.20.40.30.40.31.93.02.40.30.30.2
Selling, General & Administrative Expenses (SG&A)1.42.02.14.17.29.27.04.85.68.37.011.710.911.712.510.9
Operating Income
% margin
(1.7)
0.0%
(2.4)
(15,528.1%)
(1.2)
(418,616.7%)
(4.1)
(4,248.3%)
(7.2)
(3,792.8%)
(8.9)
(1,907.1%)
(6.5)
(679.7%)
(4.4)
(672.4%)
(6.5)
(1,429.6%)
(7.7)
(1,183.0%)
(7.9)
(556.9%)
(13.8)
(975.8%)
(0.7)
(53.2%)
(13.5)
(948.2%)
(15.3)
(1,014.2%)
(13.9)
(782.1%)
Interest Income0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Interest Expense0.10.10.10.20.30.60.40.40.00.00.00.00.00.010.70.0
Pre-tax Income0.0(1.8)(1.4)(4.5)(7.4)(9.4)(6.8)(4.8)(6.5)(7.7)(10.1)(19.4)(25.9)(20.3)(25.7)(14.0)
Income Tax
% effective tax rate
0.1
0.0%
0.4
(25.4%)
0.0
0.0%
0.2
(5.1%)
0.3
(3.5%)
0.6
(6.8%)
0.4
(5.5%)
0.0
0.0%
0.0
0.0%
0.1
(0.7%)
(2.2)
22.1%
8.2
(42.1%)
11.8
(45.7%)
(0.7)
3.3%
10.5
(40.7%)
0.0
0.0%
Net Income
% margin
(1.8)
0.0%
(2.9)
(18,378.5%)
(1.4)
(469,690.6%)
(4.5)
(4,643.0%)
(7.4)
(3,931.8%)
(9.4)
(2,009.4%)
(6.8)
(718.1%)
(4.8)
(732.1%)
(6.5)
(1,429.6%)
(7.7)
(1,183.0%)
(10.1)
(714.5%)
(27.6)
(1,952.2%)
(37.7)
(3,010.7%)
(19.7)
(1,383.6%)
(36.2)
(2,405.1%)
(14.0)
(785.6%)
EPS(65,282.52)(96,407.67)(36,559.70)(52,786.81)(26,794.78)(16,051.71)(11,057.55)(4,601.85)(462.31)(243.50)(157.40)(192.02)(63.10)(7.16)(9.92)(3.48)
Diluted EPS(65,282.52)(96,407.67)(36,559.70)(52,786.81)(26,794.78)(16,051.71)(11,057.55)(4,601.85)(462.31)(243.50)(157.40)(192.02)(63.10)(7.16)(9.92)(3.48)
EBITDA
% margin
(1.7)
0.0%
(2.8)
(17,857.6%)
(1.2)
(417,773.3%)
(4.3)
(4,401.3%)
(7.2)
(3,793.9%)
(8.8)
(1,871.6%)
(6.4)
(671.8%)
(4.3)
(660.4%)
(6.4)
(1,411.5%)
(6.0)
(913.5%)
(7.7)
(546.4%)
(12.4)
(879.4%)
(11.5)
(915.0%)
(12.1)
(853.9%)
(14.0)
(926.9%)
(13.2)
(740.5%)

Discover more Stock Ideas

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
More ideas -->

FAQ

1) What is Predictive Oncology Inc.'s Rule of 40 (EBIT margin)?

As of today, Microsoft Corp's last 12-month Rule of 40 (EBIT margin) is (982.0%), based on the financial report for Sep 30, 2024 (Q3’2024). The average annual Rule of 40 (EBIT margin) for Predictive Oncology Inc. have been (1,097.5%) over the past three years, and (1,183.7%) over the past five years.

2) Is Predictive Oncology Inc.'s Rule of 40 (EBIT margin) Good?

As of today, Predictive Oncology Inc.'s Rule of 40 (EBIT margin) is (982.0%), which is lower than industry median of (8.0%). It indicates that Predictive Oncology Inc.'s Rule of 40 (EBIT margin) is Bad.

3) How does Predictive Oncology Inc.'s Rule of 40 (EBIT margin) compare to its peers?

As of today, Predictive Oncology Inc.'s Rule of 40 (EBIT margin) is (982.0%), which is lower than peer median of 18.3%. The list of peers includes ISRG, RMD, COO, HOLX, BDX, WST, ALC, ATR, MASI, BAX.